The apparent body clearance of chloramphenicol was investigated in 21 hospitalized adult patients on 27 occasions. Apparent body clearance was found to be significantly lower (1.99 ± 1.49 ml/min per kg) in patients with total serum bilirubin concentrations of >1.5 mg/100 ml than in patients with serum bilirubin concentrations of c1.5 mg/100 ml (3.57 ± 1.72 ml/min per kg; P < 0.001). Serum protein binding of chloramphenicol was lower in cirrhotic patients (42.2 ± 6.8% bound) than in normal adults (53.1 ± 5.2% bound; P < 0.001). Low binding of chloramphenicol was also found in the serum of premature neonates (32.4 ± 8.2% bound; P < 0.001). Reduced binding in neonates implies the need for a lower therapeutic range of total chloramphenicol concentration (3.5 to 13.9 ,ug/ml) compared with the usual adult range (5 to 20 Ag/ml). Finally, three case reports are presented which demonstrate marked abnormalities and intrasubject variation in chloramphenicol clearance.
The apparent body clearance of chloramphenicol was investigated in 21 hospitalized adult patients on 27 occasions. Apparent body clearance was found to be significantly lower (1.99 ± 1.49 ml/min per kg) in patients with total serum bilirubin concentrations of >1.5 mg/100 ml than in patients with serum bilirubin concentrations of c1.5 mg/100 ml (3.57 ± 1.72 ml/min per kg; P < 0.001). Serum protein binding of chloramphenicol was lower in cirrhotic patients (42.2 ± 6.8% bound) than in normal adults (53.1 ± 5.2% bound; P < 0.001). Low binding of chloramphenicol was also found in the serum of premature neonates (32.4 ± 8.2% bound; P < 0.001). Reduced binding in neonates implies the need for a lower therapeutic range of total chloramphenicol concentration (3.5 to 13.9 ,ug/ml) compared with the usual adult range (5 to 20 Ag/ml). Finally, three case reports are presented which demonstrate marked abnormalities and intrasubject variation in chloramphenicol clearance.
As a result of the activity of chloramphenicol (CAP) against anaerobic organisms (5) and Haemophilus influenzae which are resistant to ampicillin (2) , it has gained new popularity. Use of this agent is, however, coupled with serious potential toxicities. Idiosyncratic aplastic anemia is extremely rare (25) but must be weighed as a factor in the choice of this agent. Dose-related, and thus avoidable, toxicities include normocytic bone marrow suppression, which is associated with serum concentrations exceeding 25 yig/ml and prolonged courses of therapy (13, 19, 25) , and a syndrome consisting of cardiovascular collapse, gastrointestinal distress, respiratory depression, and coma. This symptom complex, commonly referred to as the grey syndrome, has been reported in neonates (3, 12, 22, 24) , infants (4) , and adults (11, 23) and is associated with serun CAP concentrations ranging from 40 to 200 ,ug/ml.
CAP is extensively metabolized. In normal adults approximately 90% of an oral dose is excreted in urine within 24 h (8) . Of this quantity, only 5 to 10% is excreted as unchanged drug (7) . The principal metabolite is a glucuronide which is formed in the liver and is actively secreted by the kidney (6) . It is reasonable to expect decreased clearance of the drug in patients with impaired liver function. McCurdy (13) and Suhrland and Weisberger (20) Bilirubin (10 mg/100 ml from bovine galLstones; Sigma Chemical Co., St. Louis, Mo.) was added to the sera from normal subjects and premature infants to evaluate the potential displacing effect of bilirubin on CAP binding. CAP binding to high-and low-binding control sera was determined on nine and six separate occasions, respectively, in an attempt to evaluate the precision of binding determinations.
Analysis of total CAP concentration in all samples was performed by high-performance liquid chromatography (8) . This method has been shown to be specific for CAP in the presence of metabolites, CAP-succinate ester, and other antibiotics. The analytic procedure was as follows. The sample (0.1 ml) was shaken with an equal volume of 1.0 N sodium acetate buffer, pH 4.6. This solution was extracted with 1 ml of ethyl acetate containing 12.5 gAg of 5-ethyl-5-p-tolylbarbituric acid (99+% pure; Aldrich Chemical Co. Inc., Milwaukee, Wis.) per ml as an internal standard. The organic phase was evaporated to dryness under a nitrogen stream at 40°C. The residue was redissolved with 0.2 ml of methanol, and 0.02 ml of this solution was injected into the chromatograph. Separation was accomplished by using a 25-cm C-18 gt-Bondapak column (PN-27324; Waters Associates, Milford, Mass.) at 40°C. The mobile phase was 25% acetonitrile (Photrex grade; J. T. Baker Chemical Co., Phillipsburg, N.J.) in 0.1 N acetate buffer, pH 6 .0. Ultraviolet absorbance of CAP and the internal standard was determiined at 270 nm. Retention times for CAP and the internal standard were 3.0 and 4.8 min, respectively. The procedure demonstrated between-day coefficients of variation of 13.7% on 7.5-,ug/ml control samples and 6.1% on 25- Ig/ml control samples. During the above-described studies, three critically ill patients were examined. By appropriate prospective sampling and by obtaining leftover serum from clinical ANTIMICROB. AGENTS CHEMOTHER.
laboratories, a detailed evaluation of the pharmacokinetic characteristic-of CAP was possible. RESULTS Figure 1 shows CAP serum concentrations as related to weight-corrected dose. Patients were divided into two groups on the basis of normal (<1.5 mg/100 ml) or elevated (21.5 mg/100 ml) total serum bilirubin concentration. This parameter was used as a marker for impaired liver function. Extrahepatic factors which cause elevation of serum bilirubin concentration were not present in study patients. In patients with normal liver function, regression analysis demonstrated a significant correlation between concentration and dose correlation coefficient (0.68; P < 0.01). No correlation was found for patients with bilirubin -1.5 mg/100 ml. Figure 2 shows the results of ABC calculations. Points joined by a line indicate serial determinations of ABC in the same patient on different days. The mean for patients with normal liver function was 3.57 ± 1.72 ml/min per kg. In patients with impaired liver function, the mean clearance was 1.99 ± 1.49 ml/min per kg. The difference between the mean clearances of the two patient groups was statistically signifi-
The results of protein binding studies are shown in Fig. 3 . In normal adults, the mean binding was 53.1 ± 5.2%. When bilirubin was added to the serum before dialysis, there was no statistically significant change in binding (50.9 ± 2.7%).
In cirrhotic patients, the mean binding was 42.2 ± 6.8%. This was significantly (P < 0.001) (ii) Case 2. R.P. was a 17-year-old 72-kg white male admitted to the hospital in septic shock on 25 March 1978. Therapy with gentamicin, oxacillin, CAP, methylprednisolone, and dopamine was begun. Three doses of 1.8 g. of CAP, followed by four dose of 1.2 g of CAP, were administered at 6-h intervals. Serum creatinine was 4.2 mg/ 100 ml on admission and increased to 7.4 mg/ 100 ml by 50 h, at which time continuous peritoneal dialysis was begun. Serum creatinine stabilized in the range of 7 to 8 mg/100 ml during the period of study. Serum glutamic oxalacetic transaminase, serum glutamic pyruvic transaminase, and lactic dehydrogenase were only mildly elevated during the study (47 to 62 vs. 5 to 19 in normals; 35 to 43 vs. 4 to 25 in normals; and 252 to 274 vs. 55 to 134 in normals, respectively). Arterial oxygen tension remained low (50 to 80 mm of Hg) despite high percentages of inspired oxygen (50 to 90%) during treatment. Initial hypotension was rapidly reversed by the infusion of dopamine (7.5 to 15 iLg/kg per min). At 75 h, the dopamine infusion was discontinued, and the blood pressure of the patient remained stable. All CAP doses and serum concentrations obtained during the treatment are shown in Fig. 5 . The patient recovered over the course of 2 months and was discharged without sequelae.
The patient demonstrated an unusual degree of accumulation of CAP and a dramatically increased elimination half-life (19.1 h) (Fig. 5) . If a normal volume of distribution of 0.92 liters/kg is assumed (1), the calculated CAP body clearance of the patient (volume of distribution times elimination constant) (17) was only 0.55 ml/min per kg, which is a value markedlv below those reported previously. At approximately 80 h, his clearance began to increase dramatically, and by 130 h, his ABC bad returned to normal (4.28 ml/ min per kg). This increased clearance coincided with the discontinuation of dopamine infusion. As dopamine is not expected to decrease mesenteric blood flow at the dose employed, one might expect that the improvement in clearance after the discontinuation of dopamine was coincidental or that dopamine was discontinued in response to an overall improvement in the condition of the patient, which resulted in increased CAP clearance. This patient also demonstrated marked variability in CAP clearance.
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(iii) Case 3. K. S. was a 4-month-old 5-kg white female who was admitted to the hospital after suffering respiratory arrest at home. She had been well until 1 day before admission, when she became febrile and listless. Moderate hepatomegaly was noted on admission. Indexes of liver function were only slightly abnormal on admission but became markedly elevated by 72 h after admission (total bilirubin, 5.5 mg/100 ml; serum glutamic oxalacetic transaminase, 394 U; serum glutamic pyruvic transaminase, 129 U; lactic dehydrogenase, 1,399 U). Renal function remained normal during the period of observation. Antibiotic coverage with gentamicin, oxacillin, and CAP was begun. The dosage of CAP employed and the resultant serum concentrations are shown in Fig. 6 . At 59 h, the patient suffered a second respiratory arrest and cardiovascular collapse. At this time, a serum sample was assayed for CAP concentration. The result (58.8 ,ug/ml) was above the desired therapeutic range, and therapy was discontinued. During the subsequent 48-h period, multiple serum samples were assayed. The half-life of CAP elimination was markedly increased (36 h).
Assuming that drug administration can be approximated by a constant infusion, the volume of distribution was estimated by the method of Sawchuk and Zaske (18) pected from an 85-mg dose of CAP administered every 6 h. The close agreement between observed and predicted values (Fig. 6, upper curve) indicates that the low clearance which this patient demonstrated (0.45 ml/min per kg) was present on admission. Also shown is a simulation (Fig. 6, lower curve) of the dosage regimen which would have been required in this patient to produice serum concentrations in the range of 10 to 20 ,g/ml (52-mg doses, given every 24 h). The patient expired at 100 h after admission. Autopsy revealed massive necrosis of the liver with fatty infiltration. The exact etiology of this injury was not found. This case demonstrated the extreme to which CAP elimination can be reduced in patients with severe liver impairnent. DISCUSSION A significant correlation (correlation coefficient, 0.68) was found between serum trough concentration and dose in patients with nonnal liver function (Fig. 1 Our observations indicated that patients with normal liver function receiving usual doses generally have serum concentrations below 25 ,ug/ ml. In one-half of our patients with impaired liver function, however, serum concentrations were above 25 ,tg/ml. An increased incidence of reversible bone marrow toxicity is associated with serum concentrations that exceed 25 ,ug/ml (13, 19, 25) , and grey syndrome has been reported in patients with somewhat higher serum concentrations (3, 4, 11, 12, (22) (23) (24) . Thus, monitoring of CAP serum concentrations may not be needed in patients with normal liver function, but it would appear to be of value in patients with cirrhosis.
Our CAP clearance values (ABC) were compared with clearance values calculated by conventional means in which the data of Azzollini et al. (1) were used. These authors reported serum CAP concentrations after administration of a single intravenous dose of 10 mg/kg. Their serum concentration data were fit to either a one-compartment or a two-compartment pharmacokinetic model by NONLIN computer program (14) to yield the best fit to observed concentrations. The volume of distribution (VD), elimination constant (K), and clearance (Total body clearance = VD x K) were calculated (Table 1) . Their clearance data also appear in Fig. 2 .
Their nonnal subjects demonstrated a significantly higher (P < 0.01) clearance value than their cirrhotic patients (4.70 ± 1.11 versus 2.78 ± 1.02 ml/min per kg). There was no significant difference between their normal subjects and our patients with normal liver function; nor was there a significant difference between our cirrhotic patients and the patients studied by Azzollini et al. (1) . The agreement between ABC and total body clearance values seen in Fig. 2 supports the use of the ABC parameter as an initial clearance estimate in the patient population studied. Azzollini et al. (1) also reported a significant correlation between the half-life of CAP and serum bilirubin concentration. Our observation of reduced clearance in patients with total bilirubin concentrations of 21.5 mg/ 100 ml confirms their results. As approximately 90% of the drug is metabolized by the liver (8), compromised liver function would be expected to diminish clearance and increase serum concentrations. This is consistent with our observations ( Fig. 1 and 2) .
Protein binding was found to be decreased in serum from patients suffering from liver disease. This phenomenon may be due to a lower total serum protein concentration in cirrhotic patients. Binding in premature infants was also significantly lower, compared with that in normal adults. This is consistent with observations by Kurz et al. (9) , who reported a mean binding of 66.0% in their pooled adult plasma and 45.9% in pooled cord plasma collected immediately after delivery. The ratio of adult to cord serum binding reported by these investigators (1.6) was identical to the value obtained in our study.
These authors determined that some other factor in addition to reduced total protein concentrations in neonatal serum was responsible for the reduced binding in these patients. Nonprotein constituents which may be present in the cord plasma were implicated (9) . Different albumin properties which have been reported in newborns (15) may be responsible for the altered binding characteristics. Bilirubin has been shown to displace certain acidic drugs from albumin binding sites (10) . Our study, however, demonstrated no such effect on the binding of neutral CAP.
The decreased binding observed in the sera of our cirrhotic patients would be expected to result in a mean free serum CAP concentration which is 23.4% higher than that observed in normal adults (42.2 versus 53.1% bound). This difference is probably not clinically significant.
In premature infants, however, the mean free concentration was 44.1% higher than in normal adults (32.4 versus 53.1% bound). The recommended therapeutic range for total serum concentration is 5 to 20 jsg/ml (16) . This range of totakconcentrations would generate a free concentration range of 2.3 to 9.4 ig/ml in normal adults (53.1% bound). In premature infants, total serum concentrations of only 3.5 to 13.9 ,g/ml would yield the same free drug concentrations (32.4% bound). This significant difference in therapeutic range should be appreciated when interpreting serum concentration data. The case reports presented are self explanatory. It is of significance that in the rather limited observation of CAP usage in this study, three cases with dramatic alterations in the pharmacokinetic behavior of this drug should appear. It is likely that such unusual behavior may occur with a previously unsuspected frequency. If shock plays a major role in these changes, one could predict a cycle in which shock produces elevated levels of CAP which, in turn, produce cardiovascular collapse and respiratory arrest. 
